Caris Life Sciences shares rose in Monday trading after Jefferies initiated coverage with a Buy rating and a $28 price target, resetting near-term investor focus on upside potential from the company’s precision oncology platform and growth trajectory. The initiation provided a fresh catalyst for a stock that has been volatile since its public-market debut and has recently traded well below prior highs.

The initiation lands as Caris continues to highlight expansion of its AI-enabled oncology decision-support tools and as investors watch for further progress tied to its early-detection roadmap. Management has also framed 2026 as a key year, with the company previously guiding to $1.0 billion to $1.02 billion of full-year 2026 revenue following strong 2025 growth, keeping the narrative centered on scaling volumes, improving pricing, and operating leverage.

Beyond research coverage, Caris has had financing headlines in April, including a new senior secured credit package involving lenders managed by Blue Owl Capital and Blackstone, which can be read as both added liquidity for expansion and a new variable in leverage and interest expense. Near-term attention is likely to remain on upcoming clinical/technology updates around its multi-cancer early detection efforts and continued AI product rollouts, which have been central to the company’s commercialization story.